Sheron Johnson

Sheron Johnson supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that advance regulatory science and sustain scientific infrastructure. She manages a diverse portfolio of contracts focused on professional, scientific, and technical services essential to the FDA’s public health mandate, including research support, analytical instrumentation maintenance, and clinical consulting. Her work directly enables the agency’s ability to evaluate drug safety, validate medical device performance, and ensure the integrity of laboratory operations through strategic sourcing and compliance with federal acquisition regulations. Johnson maintains consistent contracting relationships with specialized vendors such as Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., reflecting a preference for niche, high-expertise providers in life sciences and regulatory support. These partnerships are typically structured as task-order or indefinite-delivery/indefinite-quantity (IDIQ) contracts, emphasizing technical precision, scientific rigor, and compliance with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). Her procurement approach prioritizes subject-matter expertise over volume, fostering long-term vendor collaboration grounded in regulatory alignment. Her contracting patterns show a strong emphasis on open competition, with 75% of awards issued without set-aside designations, while 25% are reserved for total small business participation under FAR 19.5. This balance reflects a strategic commitment to leveraging small business innovation while maintaining flexibility to meet urgent scientific and operational demands. She does not favor specific socioeconomic categories like 8(a) or HUBZone but consistently integrates qualified small businesses into the procurement stream where their capabilities align with technical requirements. Johnson’s primary procurement focus lies in NAICS 541618 (Management Consulting), 541714 (Biotechnology R&D), 541715 (Physical and Life Sciences R&D), and 541990 (Other Professional Services), underscoring her expertise in procuring scientific consulting, preclinical research, laboratory analysis, and regulatory compliance support. Her work is deeply rooted in the domains of pharmaceutical development, toxicology, and biomedical testing, ensuring FDA’s scientific infrastructure remains agile and technically robust.